See more : AA Plus Tradelink Limited (AAPLUSTRAD.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Emmaus Life Sciences, Inc. (EMMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Emmaus Life Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Australian Ethical Investment Ltd. (AEF.AX) Income Statement Analysis – Financial Results
- Svaraj Trading and Agencies Limited (ZSVARAJT.BO) Income Statement Analysis – Financial Results
- AUX International Holdings Limited (2080.HK) Income Statement Analysis – Financial Results
- Southern Magnesium and Chemicals Limited (SOUTHMG.BO) Income Statement Analysis – Financial Results
- Newbury Street Acquisition Corporation (NBST) Income Statement Analysis – Financial Results
Emmaus Life Sciences, Inc. (EMMA)
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.60M | 18.39M | 20.61M | 23.17M | 22.75M | 1.32M | 128.50K | 85.10K | 100.10K | 135.10K | 130.90K | 115.00K | 745.90K | 638.50K | 700.10K | 773.50K | 238.40K | 0.00 | 0.00 | 0.00 | 6.80K | 7.89K | 8.28K | 14.26K | 20.00K |
| Cost of Revenue | 1.34M | 2.59M | 3.31M | 2.25M | 1.09M | 827.40K | 53.50K | 5.50K | 4.90K | 73.00K | 142.60K | 132.00K | 147.10K | 135.10K | 131.60K | 163.20K | 166.20K | 0.00 | 0.00 | 0.00 | 885.00 | 1.21K | 1.15K | 5.78K | 10.00K |
| Gross Profit | 28.26M | 15.80M | 17.30M | 20.92M | 21.66M | 488.10K | 75.00K | 79.60K | 95.20K | 62.10K | -11.70K | -17.00K | 598.80K | 503.40K | 568.50K | 610.30K | 72.20K | 0.00 | 0.00 | 0.00 | 5.91K | 6.68K | 7.13K | 8.48K | 10.00K |
| Gross Profit Ratio | 95.47% | 85.93% | 83.93% | 90.30% | 95.19% | 37.10% | 58.37% | 93.54% | 95.10% | 45.97% | -8.94% | -14.78% | 80.28% | 78.84% | 81.20% | 78.90% | 30.29% | 0.00% | 0.00% | 0.00% | 86.98% | 84.66% | 86.15% | 59.49% | 50.00% |
| Research & Development | 1.19M | 1.73M | 4.11M | 2.41M | 2.18M | 1.38M | 1.36M | 794.20K | 783.80K | 1.45M | 1.29M | 853.70K | 924.80K | 1.12M | 2.14M | 2.10M | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 14.89M | 13.17M | 13.44M | 13.68M | 17.01M | 7.36M | 4.42M | 2.50M | 1.62M | 2.03M | 2.54M | 2.94M | 4.27M | 5.02M | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.40K | 15.55K | 20.00K |
| Selling & Marketing | 8.64M | 7.49M | 5.88M | 4.87M | 6.98M | 1.99M | 1.40M | 550.50K | 347.90K | 390.20K | 366.30K | 997.10K | 1.23M | 870.90K | 915.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.53M | 20.66M | 19.32M | 18.54M | 23.99M | 9.36M | 5.82M | 3.05M | 1.97M | 2.42M | 2.90M | 3.94M | 5.50M | 5.89M | 4.80M | 3.99M | 1.90M | 416.21K | 28.58K | 261.09K | 144.54K | 17.06K | 16.40K | 15.55K | 20.00K |
| Other Expenses | 0.00 | -3.98M | 0.00 | 0.00 | -3.34M | 0.00 | 0.00 | 306.70K | 0.00 | 44.10K | 0.00 | 0.00 | 381.70K | 0.00 | 320.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 24.72M | 22.39M | 23.43M | 20.95M | 26.17M | 10.73M | 7.18M | 3.85M | 2.75M | 3.88M | 4.19M | 4.79M | 6.43M | 7.01M | 6.94M | 6.08M | 3.34M | 416.21K | 28.58K | 261.09K | 144.54K | 17.06K | 16.40K | 15.55K | 20.00K |
| Cost & Expenses | 26.06M | 24.98M | 26.74M | 23.20M | 27.26M | 11.56M | 7.23M | 3.85M | 2.76M | 3.95M | 4.33M | 4.92M | 6.58M | 7.14M | 7.07M | 6.25M | 3.51M | 416.21K | 28.58K | 261.09K | 145.43K | 18.27K | 17.55K | 21.33K | 30.00K |
| Interest Income | 681.00K | 680.00K | 761.00K | 2.30M | 232.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.38M | 0.00 | 0.00 | 99.50K | 104.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 11.00 | 0.00 |
| Interest Expense | 7.38M | 5.01M | 3.10M | 5.99M | 27.39M | 86.30K | 6.60K | 2.72M | 257.40K | 0.00 | 1.29M | 0.00 | 7.57M | 1.67M | 2.14M | 0.00 | 115.60K | 18.53K | 30.57K | 4.51K | 725.00 | 458.00 | 203.00 | 0.00 | -10.00K |
| Depreciation & Amortization | 32.00K | 53.00K | 59.00K | 60.00K | 73.00K | 113.10K | 48.70K | 7.20K | 7.60K | 10.30K | 13.00K | 18.80K | 11.90K | 9.40K | 9.10K | 6.30K | 19.90K | 225.00K | 39.33K | 0.00 | 96.00 | 0.00 | 65.00 | 231.00 | -20.00K |
| EBITDA | 3.57M | -5.50M | -12.76M | 28.00K | -26.98M | -10.13M | -7.05M | -3.19M | -3.12M | -2.63M | -4.19M | -4.79M | -1.29M | -7.80M | -6.67M | -5.47M | -3.25M | 553.80K | -1.09M | -261.09K | -138.63K | -10.38K | -9.20K | -6.84K | -30.00K |
| EBITDA Ratio | 12.07% | -35.81% | -39.02% | 0.07% | -36.01% | -769.82% | -5,490.19% | -4,726.56% | -2,179.42% | -3,654.92% | 875.63% | -4,162.70% | -779.93% | -812.51% | -850.25% | -706.89% | -1,407.97% | 0.00% | 0.00% | 0.00% | -2,041.27% | -131.43% | -111.20% | -47.98% | -150.00% |
| Operating Income | 3.54M | -6.59M | -6.13M | -43.00K | -4.51M | -10.24M | -7.10M | -3.77M | -2.66M | -3.82M | -4.20M | -4.81M | -5.83M | -6.51M | -6.69M | -5.47M | -3.27M | -416.21K | -28.58K | -261.09K | -138.63K | -10.38K | -9.27K | -7.07K | -10.00K |
| Operating Income Ratio | 11.96% | -35.81% | -29.73% | -0.19% | -19.83% | -778.78% | -5,528.09% | -4,426.32% | -2,653.75% | -2,825.17% | -3,209.01% | -4,179.04% | -781.53% | -1,018.79% | -955.88% | -707.71% | -1,371.48% | 0.00% | 0.00% | 0.00% | -2,039.86% | -131.43% | -111.99% | -49.60% | -50.00% |
| Total Other Income/Expenses | -7.33M | -3.98M | -9.79M | 1.01M | -50.17M | -317.80K | -6.60K | -2.17M | -724.60K | 1.16M | -6.69M | 1.89M | -2.50M | -1.67M | -1.82M | 104.00K | -8.70K | -18.53K | 8.76K | -4.51K | -629.00 | -458.00 | -197.00 | 11.00 | -10.00K |
| Income Before Tax | -3.79M | -10.63M | -15.92M | 719.00K | -54.68M | -10.33M | -7.11M | -5.94M | -3.38M | -2.65M | -10.89M | -2.91M | -8.87M | -8.17M | -8.52M | -5.37M | -3.28M | -434.74K | -19.82K | -265.60K | -139.26K | -10.83K | -9.47K | -7.06K | -20.00K |
| Income Before Tax Ratio | -12.81% | -57.78% | -77.25% | 3.10% | -240.32% | -785.34% | -5,533.23% | -6,978.73% | -3,377.62% | -1,965.14% | -8,317.19% | -2,534.26% | -1,188.54% | -1,280.06% | -1,216.25% | -694.26% | -1,375.13% | 0.00% | 0.00% | 0.00% | -2,049.12% | -137.23% | -114.37% | -49.53% | -100.00% |
| Income Tax Expense | -59.00K | 60.00K | 25.00K | -381.00K | 164.00K | 1.90K | 2.60K | 2.00K | 5.00K | 5.20K | 800.00 | 1.90K | 1.30K | 800.00 | 7.20K | 1.40K | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 20.00K |
| Net Income | -3.73M | -10.69M | -15.95M | 1.35M | -54.84M | -9.60M | -7.11M | -5.94M | -3.38M | -2.66M | -10.91M | -3.41M | -8.87M | -8.17M | -8.52M | -5.37M | -3.28M | -435.54K | -20.62K | -266.40K | -140.06K | -11.63K | -10.27K | -7.86K | -40.00K |
| Net Income Ratio | -12.61% | -58.10% | -77.37% | 5.84% | -241.04% | -729.66% | -5,535.25% | -6,981.08% | -3,376.02% | -1,970.98% | -8,332.62% | -2,962.43% | -1,188.71% | -1,280.19% | -1,217.28% | -694.44% | -1,375.46% | 0.00% | 0.00% | 0.00% | -2,060.89% | -147.37% | -124.03% | -55.14% | -200.00% |
| EPS | -0.07 | -0.22 | -0.32 | 0.03 | -1.30 | -11.08 | -15.15 | -55.54 | -39.83 | -32.17 | -172.68 | -2.14K | -5.69K | -5.63K | -7.35K | -7.65K | -2.11K | -279.91 | -13.25 | -171.21 | -90.01 | -7.48 | -6.60 | -5.05 | 0.00 |
| EPS Diluted | -0.07 | -0.22 | -0.32 | 0.03 | -1.30 | -11.08 | -15.15 | -55.54 | -39.83 | -32.17 | -172.68 | -2.14K | -5.69K | -5.63K | -7.35K | -7.65K | -2.11K | -279.91 | -13.25 | -171.21 | -90.01 | -7.48 | -6.60 | -5.05 | 0.00 |
| Weighted Avg Shares Out | 53.11M | 49.44M | 49.25M | 48.90M | 42.26M | 866.59K | 469.57K | 106.97K | 84.84K | 82.77K | 63.17K | 1.60K | 1.56K | 1.45K | 1.16K | 702.00 | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 49.31M |
| Weighted Avg Shares Out (Dil) | 53.11M | 49.44M | 49.25M | 48.90M | 42.26M | 866.60K | 469.57K | 106.97K | 84.84K | 82.77K | 63.17K | 1.60K | 1.56K | 1.45K | 1.16K | 702.00 | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 1.56K | 49.31M |
OTC Markets Group Welcomes Emmaus Life Sciences, Inc. to OTCQX
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company, has qualified to trade on the...
Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021
TORRANCE, Calif., Sept. 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced financial results for the six months ended June 30, 2021.
Emmaus Life Sciences Announces Bahrain Temporary License of Endari®
TORRANCE, Calif. , Aug. 17, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that on August 12, 2021, the National Health Regulatory Authority (NHRA) of...
Emmaus Life Sciences Provides SEC Reporting Update
TORRANCE, Calif., Aug. 10, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that it has restated its financial statements for the fiscal year ended December 31, 2020, and that investors should...
Texas Adds Endari® to Latest Preferred Drug List
TORRANCE, Calif., Aug. 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that Endari® has been included on the Preferred Drug List published on July 29, 2021, by Texas...
Emmaus Life Sciences Provides Interim Sales Information
TORRANCE, Calif., July 22, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today preliminary sales results for the six months ended June 30, 2021.
Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manage Early Access Program
TORRANCE, Calif., June 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) of Emmaus'...
Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari® to the Saudi Food & Drug Authority
TORRANCE, Calif., May 26, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that its application for Marketing Authorization (MA) for Endari® in the Kingdom of...
Source: https://incomestatements.info
Category: Stock Reports